Abstract
Human immunodeficiency virus (HIV) patients have more aggressive presentation of colorectal cancer (CRC) and less favourable outcome. Bevacizumab is an antiangiogenic agent that has emerged as a major drug for metastatic CRC. However, few data are available on the safety of bevacizumab in HIV patients. In the light of a case study, we briefly draw intention on how angiogenesis inhibitors could interact with antiviral tri-therapy.
Keywords:
AIDS,; Bevacizumab,; Targeted therapies,; Toxicity.
MeSH terms
-
Adenocarcinoma / diagnosis
-
Adenocarcinoma / drug therapy*
-
Angiogenesis Inhibitors / administration & dosage
-
Angiogenesis Inhibitors / adverse effects
-
Angiogenesis Inhibitors / therapeutic use*
-
Anti-HIV Agents / administration & dosage
-
Anti-HIV Agents / adverse effects
-
Anti-HIV Agents / therapeutic use*
-
Antibodies, Monoclonal, Humanized / administration & dosage
-
Antibodies, Monoclonal, Humanized / adverse effects
-
Antibodies, Monoclonal, Humanized / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bevacizumab
-
Colorectal Neoplasms / diagnosis
-
Colorectal Neoplasms / drug therapy*
-
HIV Infections / drug therapy*
-
Humans
-
Male
-
Middle Aged
-
Neovascularization, Pathologic / drug therapy
-
Treatment Outcome
Substances
-
Angiogenesis Inhibitors
-
Anti-HIV Agents
-
Antibodies, Monoclonal, Humanized
-
Bevacizumab